Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing

Eugenie S. Kleinerman  
*The University of Texas MD Anderson Cancer Center*

Ling Yu  
*The University of Texas MD Anderson Cancer Center*

Jasmine Dao  
*Nightlight Urgent Care*

Andrea A. Hayes-Jordan  
*The University of Texas MD Anderson Cancer Center*

Brock Lindsey  
*West Virginia University*

See next page for additional authors

Follow this and additional works at: [https://researchrepository.wvu.edu/ctsi](https://researchrepository.wvu.edu/ctsi)

Part of the Medicine and Health Sciences Commons

Digital Commons Citation  
Kleinerman, Eugenie S.; Yu, Ling; Dao, Jasmine; Hayes-Jordan, Andrea A.; Lindsey, Brock; Kawedia, Jitesh D.; Stewart, John; and Gordon, Nancy, "Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing" (2018). *Clinical and Translational Science Institute*. 774.  
[https://researchrepository.wvu.edu/ctsi/774](https://researchrepository.wvu.edu/ctsi/774)
Research Article
Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing

Eugenie S. Kleinerman, Ling Yu, Jasmine Dao, Andrea A. Hayes-Jordan, Brock Lindsey, Jitesh D. Kawedia, John Stewart, and Nancy Gordon

1The University of Texas MD Anderson Cancer Center, Division of Pediatrics, 1515 Holcombe Blvd., Unit 0853, Houston, TX 77030, USA
2The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Research, 1515 Holcombe Blvd., Houston, TX 77030, USA
3Nightlight Urgent Care, 15551 Southwest Freeway, Sugar Land, TX 77478, USA
4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Children’s Cancer Hospital, 1515 Holcombe Blvd., Unit 1484, Houston, TX 77030, USA
5Department of Orthopedic Surgery, University of West Virginia, P.O. Box 9196, Morgantown, WV 26506-9196, USA
6The University of Texas MD Anderson Cancer Center, Pharmacy Pharmacology Research, 1515 Holcombe Blvd., Unit 0090, Houston, TX 77030, USA
7Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

Correspondence should be addressed to Eugenie S. Kleinerman; ekleiner@mdanderson.org

Received 17 August 2017; Accepted 25 October 2017; Published 21 January 2018

Academic Editor: Fritz C. Eilber

Copyright © 2018 Eugenie S. Kleinerman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Osteosarcoma is the most common malignant bone tumor in both adults and children. While the introduction of combination chemotherapy given in addition to surgery improved the overall survival from 20 to 65%, survival rates have remained stagnant for >25 years [1–3]. The lung is most common site of metastatic spread, and the majority of newly diagnosed patients have undetectable microscopic lung metastases at the time of diagnosis providing the rational for giving preoperative and postoperative chemotherapy. Despite the use of aggressive combination chemotherapy, the development of visible lung metastases continues to be the major challenge in curing this disease. For patients who
develop relapsed disease in the lung, the 5-year survival rate is only 20% [4, 5], and second-line chemotherapy has not made a significant impact on improving this outcome [6]. It is therefore critical to eradicate these micrometastases during the initial treatment period.

Prior to surgery, systemic chemotherapy serves to control the growth and size of the primary tumor to decrease the morbidity of surgery in addition to targeting the microscopic disease in the lung. Chemotherapy is stopped a few weeks before and for several weeks after surgery due to the interference of systemic chemotherapy on wound healing. Once patients recover from surgery, chemotherapy is resumed to prevent macroscopic metastases from developing. This results in a break or delay in chemotherapy administration, leaving patients untreated for a significant period of time when tumor rebound is possible. It is therefore important that this delay be as short as possible. The standard time between the surgery and the resumption of chemotherapy treatment is 2–4 weeks, but delays as much as 6–8 weeks have been reported in patients with postoperative complications such as infection or other comorbidities that lead to delayed healing [7–9]. Delays >16 days have been associated with an increased risk of relapse and a significant decrease in overall survival [7, 8]. With 21–40% of patients experiencing delays [7, 8], identifying an effective “bridge therapy” against osteosarcoma lung metastases which does not interfere with postoperative healing and can be used in the immediate postoperative period has the potential to prevent relapse and increase both the event-free and overall survival.

Wound healing is complex and includes 3 distinct phases [10, 11]. First is the inflammatory phase which consists of the recruitment of inflammatory cells, including neutrophils, mast cells, and macrophages, both M1 and M2. M2 macrophages promote cell proliferation and tissue repair, while M1 macrophages inhibit cell proliferation. The second phase involves the migration and proliferation of fibroblasts and endothelial cells [12, 13]. Tissue remodeling is the third phase. Several specific cytokines and growth factors are critical to the healing process including IL-10 and bFGF [14–17]. A potential bridge therapy candidate should not interfere with any of the three wound-healing phases.

Gemcitabine (GCB) is a deoxycytidine analogue that causes DNA damage, initiating cell death [18]. GCB given systemically together with Taxol has shown modest activity against relapsed large lung metastases [19]. The activity of aerosol delivery to target OS lung metastases has been investigated. Aerosol therapy has the advantage of delivering agents directly to the lung, the organ where micrometastases exist, resulting in increased drug concentration in the lung, decreased drug levels in the circulation, and decreased systemic toxicity [20]. Using 1/10th the systemic dose, the effect of aerosol GCB against human and mouse OS lung metastases in vivo was demonstrated [21, 22]. Maximum therapeutic activity was seen against microscopic disease. Peak serum levels following 1.0 mg/kg aerosol GCB were 200 ng/ml, significantly lower than the peak serum levels (700 ng/kg) following 1.0 mg/kg GCB given systemically. No liver, kidney, lung, or hematologic toxicity was observed in the mice following 5 weeks of aerosol GCB given 3 times/wk. In addition, aerosol GCB demonstrated significant therapeutic benefit in dogs with visible osteosarcoma lung metastases [23]. Finally, Phase I/II trials using aerosol GCB demonstrated that this therapeutic approach is safe with no significant toxicity in regard to organ function or hematologic effects [24]. Taken together, these studies indicate that aerosol GCB may be a candidate for bridge therapy between the surgery and the restarting of systemic chemotherapy. However, there are no data in mice or patients on whether aerosol GCB affects wound healing.

We therefore wished to determine whether aerosol delivery of GCB is effective against OS lung metastases without interfering with wound healing in the skin and the bone following limb amputation. We evaluated the in vivo effect of aerosol GCB initiated 48 hours after amputation of a primary OS tumor in the tibia on established OS lung metastases and the healing of bone, dorsal skin, and tail wounds. While aerosol GCB successfully eradicated the microscopic lung metastases, aerosol GCB had no significant effect on the in vivo wound-healing process.

2. Materials and Methods

2.1. Cell Lines. K7M3 murine osteosarcoma metastatic cells [21] were cultured in Dulbecco’s modified Eagle’s medium (DMEM) and supplemented with 10% fetal calf serum (HyClone, USA) and 1% penicillin/streptomycin (Lonza, USA). The cells were maintained at 37°C in a humidified atmosphere of 5% carbon dioxide in air and harvested at 80–90% confluency.

2.2. Animal Model. BALB/c mice (Charles River, USA) were anesthetized with isoflurane. K7M3 cells suspended in 10 μl of sterile phosphate-buffered saline (PBS) at a density of 1 × 10⁶ cells were injected into the tibia as previously described [22, 25]. Local tumors were detected at 3-4 weeks after injection, and the metastases were visible by 5-6 weeks [25].

2.3. Amputation. When tumor size reached 1.5 cm in diameter, the mouse was anesthetized with isoflurane and the leg was amputated above the knee joint with a sterile blade followed by the application of surgical staples. To minimize the postoperative pain, buprenorphine (0.1 mg/kg) was given as s.c. injection every 8–12 hours. The amputation wound was monitored thereafter during the aerosol PBS and GCB treatment.

2.4. Preparation of Wound Tissue. Mice were also used in the dorsal cutaneous and tail wound experiments one day after amputation. The mice were anesthetized with isoflurane, and the dorsal cutaneous skin was shaved and wiped with 70% ethanol. Full-thickness excisional wounds were made by picking up a fold of skin using a sterile disposable 6 mm biopsy punch, resulting in the generation of one wound on each side of the midline [26, 27]. A separate tail wound
10 mm × 3 mm was made on the tail of each mouse down to the fascia on the same day as the dorsal wound. The two wounds were photographed every 3 days, and dimensions were measured every 3 days, particularly noting reepithelialization of the skin [28].

2.5. Aerosol GCB Treatment. Ten mice were treated with aerosol PBS (control) or aerosol GCB at 1.0 mg/kg in 10 ml saline. For comparison of serum GCB concentration, 10 mice were treated with intraperitoneal injection of 1.0 mg/kg GCB in 0.2 ml of normal saline 3 times weekly for 3 weeks as previously described [22]. Blood was collected in tubes containing 0.75 mg of tetrahydrouridine, a cytidine deaminase inhibitor, to prevent ex vivo metabolism of gemcitabine. Blood samples were processed to separate plasma and kept at −80°C until analysis. Serum was collected at 10 min, 30 min, and 24 hours after GCB treatment. Samples were sent to Pharmacy Pharmacology Research Department for analysis of the serum GCB level.

2.6. Histology and Immunohistochemistry. Tissues from the amputation wound and dorsal cutaneous and tail wounds were collected on days 7, 14, and 2 months after the surgery and aerosol GCB treatment. Tissue sections were formalin fixed and paraffin embedded. Decalcification was performed for the amputation wound. Mast cell numbers were quantified using toluidine blue staining and counting the number of toluidine blue positive cells in 10 high-power field (h.p.f) under a 20x objective lens.

The total number of macrophages was quantified using anti-F4/80 antibody staining (ab6640, Abcam USA). M1 macrophages were identified and quantified using iNOS staining (PA5-16855, Thermo Fisher Scientific). Anti-mannose receptor antibody (ab 64,693, Abcam USA) was used to identify and quantify M2 macrophages. CD31 antibody (ab 28,364, Abcam USA) was used for endothelial cell staining; anti-VEGFR-2 (ab39256, Abcam USA) was used for VEGF staining; IL-10 and FGF-2 were measured using ab189392 (Abcam USA) and sc-1360 (Santa Cruz Biotechnology), respectively. Ki67 antibody (ab15580, Abcam USA) was used for cell proliferation and fibroblast activation; protein alpha antibody (ab53066, Abcam USA) was used for fibroblast staining. All the sections were incubated with the primary antibody overnight at 4°C in accordance with the protocols provided by companies.

2.7. Statistics. To determine the significance between two groups, we used GraphPad Prism. The statistical analysis between two groups was performed using the unpaired Student’s t-test. \( P > 0.05 \) was considered to have no significant difference.

3. Results

3.1. Serum GCB Levels following Aerosol versus Intraperitoneal Administration. We first compared the serum levels of GCB following aerosol or intraperitoneal administration. Serum GCB levels in the mice treated with GCB i.p. were 3.5-fold higher than those treated with aerosol GCB at 10 min and 30 min after administered (Figure 1).

3.2. Aerosol GCB Had No Effect on Wound Healing but Inhibited Osteosarcoma Lung Metastases. In order to mimic the clinical course of osteosarcoma, K7M3 cells were injected into the tibia. Micrometastases in the lung were confirmed by sacrificing 2 mice 3 weeks later. When the tumors measured 1.5 cm, tail and dorsal skin wounding and amputation of the affected limb were performed. The mice were divided into 2 groups and treated with either aerosol PBS or aerosol GCB 24 hours after amputation. Aerosol therapy continued twice a week for three weeks. Healing of the tail, dorsal skin, and amputation site was monitored. Skin wounds were measured 4, 7, and 10 days after the initiation of aerosol therapy. There was no difference in wound healing of the tail or dorsal skin between the aerosol PBS- and aerosol GCB-treated mice (Figures 2(a) and 2(b)). Similar to dorsal and tail wounds, aerosol GCB also did not affect the healing of the amputation site as shown by H&E staining in 3 different regions (Figure 2(c)).

To determine whether aerosol GCB inhibited lung metastasis, five mice from each treatment group were sacrificed after 3 weeks of aerosol therapy. Aerosol GCB significantly decreased the number of visible lung metastases compared to the aerosol PBS group (Figure 2(d)). Lung weights and the number of micrometastases were also significantly reduced in the aerosol GCB group (Figures 2(e) and 2(f)).

3.3. Effect of Aerosol GCB on Cell Proliferation and the Number of Fibroblasts in the Wound Areas. Ki67 is a marker of cell
Figure 2: Continued.
Figure 2: Aerosol GCB inhibited lung metastases but had no effect on wound healing in the tail, dorsal skin, or bone. (a) Representative appearance of the dorsal wound on days 1 and 10 in the mice treated with aerosol PBS (top row) or aerosol GCB (bottom row). (b) The areas of each wound in the aerosol PBS and aerosol GCB groups were measured 1, 4, 7, and 10 days after treatment ($P > 0.05$ for each group). (c) Representative H&E sections from the wounded tail, dorsal skin, and postamputation area 7 days following wounding. (d–f) Aerosol GCB inhibited the growth of osteosarcoma lung metastases as assessed visually (d), by the lung weight (e), and by the mean number of lung metastases (f) ($P < 0.01$).
proliferation. We therefore quantified the number of Ki67+ cells in the tail and dorsal skin wounds 7 days after treatment with aerosol therapy. There was no difference in the positive areas for Ki67 staining between aerosol PBS and aerosol GCB (Figure 3(a), \( P > 0.05 \) for both dorsal and tail wounds). In addition, quantification of the positive areas for fibroblasts using immunohistochemistry also showed no difference between aerosol PBS and aerosol GCB (Figure 3(b), \( P > 0.05 \) for both dorsal and tail wounds). These results demonstrate that aerosol GCB had no effect on cell proliferation or the number of fibroblast cells during wound healing.

3.4. Aerosol GCB Did Not Affect the 3 Critical Phases of Wound Healing. Wound repair typically consists of three phases: initial inflammation, followed by proliferation and finally remodeling. To determine whether aerosol GCB affects wound-induced inflammation, we quantified the number of mast cells in the wound tissues using toluidine staining, the number of macrophages using F4/80 antibody staining, and the ratio of M1 to M2 macrophages. M1 macrophages, which inhibit cell proliferation and cause tissue damage, were identified and quantified using iNOS staining. M2 macrophages, which promote cell proliferation and tissue repair, were identified and quantified using the anti-mannose receptor antibody. Both types of macrophages are important for normal wound healing as is the M1/M2 ratio. Aerosol GCB had no effect on the number of mast cells (Figure 4(a), \( P > 0.05 \)) or the number of M1 and M2 macrophages (Figure 4(b), \( P > 0.05 \)) in both tail and dorsal wounds. In addition, we showed that the M1/M2 ratio in the tail and dorsal wounds did not differ between aerosol PBS- and aerosol GCB-treated mice (M1 Figure 4(c), \( P > 0.05 \); M2 Figure 4(d), \( P > 0.05 \)). These results demonstrated that aerosol GCB does not affect the first phase of wound healing, that is, wound-induced inflammation in the mice.
We next determined whether aerosol GCB affected endothelial cell proliferation and angiogenesis, both critical functions in the second phase of wound healing.

Endothelial cells play an important role in angiogenesis in wound-healing process.

To explore whether GCB affects endothelial cell growth and recruitment in wound healing, we quantified the number of CD31+ cells (a marker expressed by endothelial cells) in dorsal and tail skin tissues 7 days after aerosol PBS or aerosol GCB. There was no difference in CD31 staining in the tail and dorsal skin wounds between aerosol PBS- and aerosol GCB-treated mice (Figure 5(a), P > 0.05). VEGFR-2 has been shown to mediate almost all of the known cellular responses to VEGF [29]. We therefore measured the density of VEGFR-2+ cells in the wound areas and once again found no difference between the aerosol PBS- and aerosol GCB-treated groups (Figure 5(b), P > 0.05). These results indicate that aerosol GCB did not inhibit angiogenesis (an important process in wound healing) or interfere with the growth of endothelial cells.

To determine whether aerosol GCB affected tissue remodeling (the third phase of wound healing), we quantified IL-10 and FGF-2 (bFGF), both of which are critical cytokines for the remodeling phase of wound healing.

IL-10 plays an important role in wound healing through its function to inhibit the infiltration of neutrophils and macrophages toward the site of the wound area during this phase [28]. We measured the positive areas of IL-10 in dorsal wound and tail wound sections 7 days after GCB treatment. Again, we showed no difference in tail or dorsal wounds (Figure 6(a), P > 0.05) between aerosol GCB- and aerosol PBS-treated mice. FGF-2 or bFGF mediates the formation of new blood vessels that are critical in the wound-healing process following surgery. Different studies demonstrated a correlation between reduced FGF-2 expression and wound-healing disorders [16, 30, 31, 33]. mRNA levels of FGF-2 were reduced during wound healing in healing-impaired genetically diabetic mice compared with control mice [38]. Expression of FGF-2 was found to be upregulated after injury in normal but not in diabetic rats. Impaired wound healing was seen in aged mice, and this impairment was associated with reduced levels of FGF-2 [33]. Finally, when FGF-2 null mice were used for wound-healing studies, they showed delayed healing, while there was no delay seen in FGF-1-knockout mice [30, 31].

3.5. Effect of Aerosol GCB on Wound Healing following Amputation. Healing of the bone and tissue following amputation and tumor removal is a critical part of the patient recovery process. We therefore monitored healing of the amputated area every other day. The amputation wound-healing process in the mice following aerosol GCB administration was not delayed compared with the mice treated with aerosol PBS. Similar to what we observed in the tail and dorsal skin wounds, there was no difference in
fibroblast proliferation, CD31 expression, VEGFR-2 expression, or the wound-associated cytokines FGF-2 (bFGF) and IL-10 between aerosol PBS and GCB groups (Figure 7).

4. Discussion

Combination chemotherapy given both pre- and postoperatively has raised the overall survival of patients with primary nonmetastatic osteosarcoma from 20 to 65% [1–3]. However, despite the use of aggressive multiagent chemotherapy, 30–35% of patients who have no detectable metastasis at the time of diagnosis develop pulmonary metastases following surgical resection and adjuvant chemotherapy. This statistic has not improved in >30 years, and patients who develop lung metastases have a significantly reduced long-term survival [4, 5]. Equally disturbing is that there has been relatively little success in treating relapsed patients with surgical resection of metastases in the lung, which is the most effective approach [32]. A recent analysis showed that the median time to progression in multiple Phase II trials in the Children’s Oncology Group for children and adolescents with relapsed osteosarcoma was ~4 months [34]. Furthermore, no responses were seen in multiple Phase I trials from a single institution [35]. Due to the absence of effective secondary agents and the poor response rates to date for relapsed patients, it is critical to identify conditions that put the patients at a higher risk for relapse.

Postoperative chemotherapy is usually not initiated for 2–8 weeks after tumor resection, depending upon the postoperative course, as chemotherapy can interfere with the wound-healing process and the production of cytokines at the wound site that have been shown to be critical to the healing process. This leaves the patient in a potential vulnerable setting as the tumor cells are free to divide and grow unchecked. Delays > 2 weeks postoperatively correlate with a poorer overall survival [7, 8]. Two independent retrospective studies showed that increased time from the definitive surgery to the resumption of chemotherapy was associated with an
increased risk of death in patients who presented with localized osteosarcoma [7, 8]. A study from the Children’s Oncology Group (COG) showed that, of 703 patients analyzed, resumption of chemotherapy ranged from 3 to 97 days following resection, with >50% of patients going >2 weeks without treatment and 22% having chemotherapy delays in excess of 21 days [8]. The times to chemotherapy resumption following surgery were dependent on several factors including the type of surgery and surgical margins. Location of the tumor (proximal versus distal extremity), tumor size (< or ≥9 cm), and % necrosis did not play a role. There was a significant decrease in overall survival in those patients that had a delay of >16 days. Patients with a delay in excess of 21 days had a 57% increased risk of death. These findings were confirmed in a more recent analysis of 77 patients with a median follow-up time of 11 years [7]. Prolonged time to the resumption of chemotherapy was once again associated with an inferior overall survival, and 75% of patients had delays beyond 21 days. Additionally concerning is that a recent study showed that the median time interval between the last neoadjuvant chemotherapy before surgery and the first dose of chemotherapy postoperatively was 50–63 days. This prolonged interval with no treatment gives the micrometastases in the lung that were not eradicated by the neoadjuvant therapy the opportunity to grow. Once a patient relapses with lung metastases, effective therapeutic options are limited as salvage chemotherapy has made no impact on long-term survival [36]. Therefore, the time a patient spends in the postoperative period without receiving chemotherapy puts the patient at significant risk. Finally, patients with a poor tumor response were found to have a significantly increased risk for relapse if there was a delay of >24 days postoperatively in the initiation of chemotherapy compared to those with a good tumor response [9]. This is the most vulnerable population as histologic response correlates with both disease-free and overall survival [9]. As chemotherapy delays increased, both populations were at higher risk for relapse and decreased survival [9]. Therefore, identifying treatments that can kill residual tumor cells in the lung which can be initiated in the immediate postoperative period because they have no adverse effect on the wound-healing process has the potential to decrease the relapse rate in both good and poor responders.

**Figure 6:** Effect of aerosol GCB on IL-10 and FGF-2 (bFGF) in the wound. The dorsal and tail skin wounds from the mice treated with aerosol PBS or aerosol GCB were examined on day 7 using (a) anti-IL-10 or (b) anti-FGF-2. The positive areas were quantified by SimplePCI groups obtained from five h.p.f areas and compared using Student’s t-test. $P > 0.05$ for all graphs.
Such a strategy can have a significant impact on the long-term survival of patients.

Our current investigations show that aerosol GCB results in significantly lower serum levels compared with its systemic administration. The dose used in our studies was 1/10th the systemic dose normally given to evaluate efficacy [22]. We have previously evaluated the efficacy of aerosol versus i.p. GCB against both primary OS and OS lung metastases [22]. Treatment in these studies was similar to that in the present investigations. When the primary tumor reached 130 mm$^3$ and micrometastases were present in the lung, the mice were treated 3 times weekly for 3 weeks. While aerosol GCB was effective against both the primary tumor and the lung metastases, i.p. GCB at the equivalent dose was only effective against the primary tumor. GCB given i.p. was not effective against the OS lung metastases [22]. Since i.p. GCB was not effective against lung metastases, we did not evaluate the effect of systemic GCB on wound healing. Our present studies focused on evaluating the simultaneous efficacy of aerosol GCB against pulmonary metastases and its effect on wound healing. The therapeutically appropriate dose of i.p. GCB would yield even higher serum GCB levels which are more likely to interfere with the healing process. The goal of our study was to evaluate the simultaneous activity of aerosol delivery of the drug on established lung metastases in the setting of a surgical resection. Supportive of the safety and tolerability of aerosol GCB are investigations showing that there was no organ or hematologic toxicity following 5 weeks of aerosol GCB given 3 times per week [21, 22]. More importantly, our present investigations show that aerosol GCB initiated 48 hours following amputation of the limb with the primary osteosarcoma tumor inhibited the growth and eradicated established micrometastases in the lung without interfering with wound healing in the skin or bone. Aerosol GCB had no effect on the 3 phases of wound healing in the dorsal skin, tail, or bone. Cell proliferation, the number of fibroblasts and mast cells, macrophage recruitment, and the ratio of Type I to Type II macrophages in the dorsal skin and tail wounds of the mice treated with aerosol GCB were similar to those of the mice treated with aerosol PBS.

Anti-VEGF therapy has been shown to result in late wound dehiscence [37]. Aerosol GCB did not inhibit endothelial cell growth or VEGF levels in the wounds and had no effect on the production of either IL-10 or FGF-2 (bFGF). Similarly, when the wound at the amputation site was examined, treatment with aerosol GCB had no effect on CD31, VEGF, bFGF, IL-10, or the number of fibroblasts. This is the first demonstration that aerosol GCB can have a therapeutic effect on lung metastases without interfering with wound healing following surgical resection of the primary tumor, a critical process in the treatment regimen for osteosarcoma. Taken together, our data suggest that the initiation of aerosol GCB in the immediate postoperative period has the potential to eradicate lung micrometastases without fear of interfering with the postoperative healing process in the skin or the bone which can delay the resumption of the systemic chemotherapy. Eradication of lung metastases during this period when systemic chemotherapy has been suspended may prevent relapse and result in an increase in the event-free and overall survival. Patients who develop lung metastases have a 5-year survival rate of only 20% [4, 5].

5. Conclusion
Salvage chemotherapy has made little impact on this survival rate. Aggressive surgical removal of the metastases in combination with salvage chemotherapy only rescues about 40% of patients [6]. As the safety of aerosol GCB has already been demonstrated in adult patients [24], our data support the concept of using aerosol GCB as a bridge after tumor resection and the initiation of clinical trials using aerosol GCB.
in children and adolescents with osteosarcoma in the immediate postoperative period.

Conflicts of Interest
The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments
The authors thank Ms. Barbara Liddle for her excellent assistance with manuscript preparation.

References

[1] F. Eilber, A. Giuliano, J. Eckardt, K. Patterson, S. Moseley, and J. Goodnight, "Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial," Journal of Clinical Oncology, vol. 5, no. 1, pp. 21–26, 1987.

[2] N. Iaffe, "Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma," Advances in Experimental Medicine and Biology, vol. 804, pp. 1–30, 2014.

[3] L. Mirabello, R. J. Troisi, and S. A. Savage, "Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program," Cancer, vol. 115, no. 7, pp. 1531–1543, 2009.

[4] J. F. Huth and F. R. Eilber, "Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases," Archives of Surgery, vol. 124, no. 1, pp. 122–126, 1989.

[5] M. D. Tabone, "Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy," Journal of Clinical Oncology, vol. 12, no. 12, pp. 2614–2620, 1994.

[6] M. A. Smith, N. L. Seibel, S. F. Altekruse et al., "Outcomes for children and adolescents with cancer: challenges for the twenty-first century," Journal of Clinical Oncology, vol. 28, no. 15, pp. 2625–2634, 2010.

[7] P. Berlanga, A. Canete, R. Diaz et al., "Presentation and long-term outcome of high-grade osteosarcoma: a single-institution experience," Journal of Pediatric Hematology/Oncology, vol. 37, no. 5, pp. e272–e277, 2015.

[8] H. Imran, F. Enders, M. Krailo et al., "Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma," Journal of Bone and Joint Surgery-American Volume, vol. 91, no. 3, pp. 604–612, 2009.

[9] P. A. Meyers, G. Heller, J. Healey et al., "Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience," Journal of Clinical Oncology, vol. 10, no. 1, pp. 5–15, 1992.

[10] C. N. Serhan and N. Chiang, "Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics," Rheumatic Disease Clinics of North America, vol. 30, no. 1, pp. 69–95, 2004.

[11] J. A. Schilling, "Wound healing," Surgical Clinics of North America, vol. 56, no. 4, pp. 859–874, 1976.

[12] P. Bainbridge, "Wound healing and the role of fibroblasts," Journal of Wound Care, vol. 22, no. 8, pp. 407–408, 2013.

[13] G. Broughton II, J. E. Janis, and C. E. Attinger, "Wound healing: an overview," Plastic and Reconstructive Surgery, vol. 117, no. 7, pp. 1e-S–32e-S, 2006.

[14] J. Hart, "Inflammation. 2: its role in the healing of chronic wounds," Journal of Wound Care, vol. 11, no. 7, pp. 245–249, 2002.

[15] J. E. Park and A. Barbul, "Understanding the role of immune regulation in wound healing," American Journal of Surgery, vol. 187, no. 5, pp. 115–165, 2004.

[16] S. Werner and R. Grose, "Regulation of wound healing by growth factors and cytokines," Physiological Reviews, vol. 83, no. 3, pp. 835–870, 2003.

[17] A. J. Singer and R. A. Clark, "Cutaneous wound healing," New England Journal of Medicine, vol. 341, no. 10, pp. 738–746, 1999.

[18] W. Plunkett, P. Huang, Y. Z. Xu, V. Heinemann, R. Grunewald, and V. Gandhi, "Gemcitabine: metabolism, mechanisms of action, and self-potentiation," Seminars in Oncology, vol. 22, no. 4, pp. 3–10, 1995.

[19] S. Okuno, J. Edmonson, M. Mahoney, J. C. Buckner, S. Frytak, and E. Galanis, "Phase II trial of gemcitabine in advanced sarcomas," Cancer, vol. 94, no. 12, pp. 3225–3229, 2002.

[20] N. V. Koshkina, B. E. Gilbert, J. C. Waldrep, A. Seryshev, and V. Knight, "Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice," Cancer Chemotherapy and Pharmacology, vol. 44, no. 3, pp. 187–192, 1999.

[21] N. Gordon and E. S. Kleinerman, "Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine," Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 23, no. 4, pp. 189–196, 2010.

[22] N. V. Koshkina and E. S. Kleinerman, "Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases," International Journal of Cancer, vol. 116, no. 3, pp. 458–463, 2005.

[23] C. O. Rodriguez Jr., R. A. Crabb, D. W. Wilson et al., "Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs," Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 23, no. 4, pp. 197–206, 2010.

[24] E. Lemarie, L. Vecellio, J. Hureaux et al., "Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study," Journal of Aerosol Medicine and Pulmonary Drug Delivery, vol. 24, no. 6, pp. 261–270, 2011.

[25] N. Gordon, N. V. Koshkina, S.-F. Jia et al., "Corruption of the fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine," Clinical Cancer Research, vol. 13, no. 15, pp. 4503–4510, 2007.

[26] Y. Ishida, J. L. Gao, and P. M. Murphy, "Chemokine receptor CX3CR1 mediates skin wound healing by promoting macrophage and fibroblast accumulation and function," Journal of Immunology, vol. 180, no. 1, pp. 569–579, 2008.

[27] H. Tomita, Y. Iwata, F. Ogawa et al., "P-selectin glycoprotein ligand-1 contributes to wound healing predominantly as a p-selectin ligand and partly as an e-selectin ligand," Journal of Investigative Dermatology, vol. 129, no. 8, pp. 2059–2069, 2009.

[28] T. Kimura, M. Sugaya, A. Blauvelt, H. Okochi, and S. Sato, "Delayed wound healing due to increased interleukin-10 expression in mice with lymphatic dysfunction," Journal of Leukocyte Biology, vol. 94, no. 1, pp. 137–145, 2013.

[29] K. Holmes, O. L. Roberts, A. M. Thomas, and M. J. Corsi, "Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition," Cellular Signalling, vol. 19, no. 10, pp. 2003–2012, 2007.
[30] D. L. Miller, S. Ortega, O. Bashayan, R. Basch, and C. Basilico, “Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice,” Molecular and Cellular Biology, vol. 20, no. 6, pp. 2260–2268, 2000.

[31] S. Ortega, M. Ittmann, S. H. Tsang, M. Ehrlich, and C. Basilico, “Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2,” Proceedings of the National Academy of Sciences, vol. 95, no. 10, pp. 5672–5677, 1998.

[32] K. A. Skinner, F. R. Eilber, E. C. Holmes, J. Eckardt, and G. Rosen, “Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma,” Archives of Surgery, vol. 127, no. 9, pp. 1065–1070, 1992.

[33] M. E. Swift, E. S. Kleinman, and L. A. DiPietro, “Impaired wound repair and delayed angiogenesis in aged mice,” Laboratory Investigation, vol. 79, no. 12, pp. 1479–1487, 1999.

[34] J. P. Lagmay, M. D. Krailo, H. Dang et al., “Outcome of patients with recurrent osteosarcoma enrolled in seven phase II trials through children’s cancer group, pediatric oncology group, and children’s oncology group: learning from the past to move forward,” Journal of Clinical Oncology, vol. 34, no. 25, pp. 3031–3038, 2016.

[35] J. A. Livingston, K. R. Hess, A. Naing et al., “Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials,” Oncotarget, vol. 7, no. 39, pp. 64421–64430, 2016.

[36] B. Kempf-Bielack, S. S. Bielack, H. Jurgens et al., “Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS),” Journal of Clinical Oncology, vol. 23, no. 3, pp. 559–568, 2005.

[37] H. Zhang, Z. Huang, X. Zou, and T. Liu, “Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials,” Oncotarget, vol. 7, no. 50, pp. 82473–82481, 2016.

[38] S. Werner, M. Breeden, G. Hüchner, D. G. Greenhalgh, and M. T. Longaker, “Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse,” Journal of Investigative Dermatology, vol. 103, no. 4, pp. 469–473, 1994.